Company / Operating Cash Flow
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. Operating Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$111.2M
FY2025
5-year range
-$263.2M / -$111.2M
FY2021-FY2025
Trend
+46.0%
vs FY2024
Sector context
#158 of 164
Health Care
What the data says
Among 164 Health Care companies, PACIFIC BIOSCIENCES OF CALIFORNIA, INC. is in the bottom 4% for operating cash flow. Operating Cash Flow has increased for 3 consecutive years, from -$263M in FY2022 to -$111M in FY2025.
Based on SEC 10-K filings.
-$111M in FY2025.
Improved from -$259M to -$111M over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 4% in Health CareTop 96% of 164This company -$111.2M Sector average $1.0B
▼
-110.7% below sector average
Key checks
Key Insights
- PACIFIC BIOSCIENCES OF CALIFORNIA, INC.'s operating cash flow has grown for 3 consecutive years.
- In FY2025, operating cash flow increased 46.0% year-over-year.
- Ranks #158 out of 164 companies in the Health Care sector.
- Peak operating cash flow was recorded in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -1.92 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$111.2M | +46.0% |
| FY2024 | -$206.1M | +20.5% |
| FY2023 | -$259.2M | +1.5% |
| FY2022 | -$263.2M | -136.7% |
| FY2021 | -$111.2M | -670.1% |
| FY2020 | $19.5M | +124.9% |
| FY2019 | -$78.3M | -17.9% |
| FY2018 | -$66.4M | +1.6% |
| FY2017 | -$67.5M | +0.6% |
| FY2016 | -$67.9M | -127.7% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026